NCT04624490 is a Phase 1 clinical trial of Hyperpolarized Xe129 in Asthma, sponsored by Mario Castro, MD, MPH.

Who is sponsoring NCT04624490?

NCT04624490 is sponsored by Mario Castro, MD, MPH.

What drugs are being tested in NCT04624490?

Interventions in NCT04624490: Hyperpolarized Xe129.

What condition does NCT04624490 study?

NCT04624490 studies Asthma, COPD, Interstitial Lung Disease, Cystic Fibrosis, Pulmonary Hypertension, Pulmonary Infection, Other Lung Disease.

Is NCT04624490 still recruiting?

NCT04624490 is currently recruiting now. Last updated 4 April 2025.

Last reviewed 2025-04-04 · How we verify

NCT04624490

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease

Recruiting now Phase 1 Last updated 4 April 2025

What this trial tests

Phase 1 trial testing Hyperpolarized Xe129 in Asthma in 260 participants. Currently enrolling.

Timeline

2 November 2020

Primary endpoint
26 October 2025

26 October 2026

Quick facts

Lead sponsor	Mario Castro, MD, MPH
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	260
Start date	2 November 2020
Primary completion	26 October 2025
Estimated completion	26 October 2026
Sites	1 location across United States

Drugs / interventions tested

Hyperpolarized Xe129 — full drug profile →

Conditions studied

Asthma — all drugs for Asthma →
COPD — all drugs for COPD →
Interstitial Lung Disease — all drugs for Interstitial Lung Disease →
Cystic Fibrosis — all drugs for Cystic Fibrosis →

Sponsor

Mario Castro, MD, MPH — full company profile →

Who can join

3 and older, any sex, with Asthma or COPD. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to develop and evaluate the usefulness of hyperpolarized (HP) 129Xe gas MRI for regional assessment of pulmonary function.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Pulmonary functional MRI: Detecting the structure-function pathologies that drive asthma symptoms and quality of life.
Kooner HK, McIntosh MJ, Desaigoudar V, Rayment JH, et al · · 2022 · cited 17× · PMID 35008127 · DOI 10.1111/resp.14197

Verify or expand the search:

Other trials of Hyperpolarized Xe129

Trials testing the same drug.

NCT06122922 — Xenon MRI in Stable Pulmonary Hypertension (Jupiter AUGEAN) · Phase 2 · withdrawn
NCT06038630 — 129Xe MRI Cardiopulmonary · Phase 2 · recruiting
NCT05766384 — Hyperpolarized 129Xe MRI Lung Health Cohort · recruiting
NCT05339386 — Developing Hyperpolarized 129Xe MRI Biomarkers for Evaluation of Pulmonary Arterial Hypertension · active not recruiting
NCT05204355 — MRI for Screening and Monitoring Scleroderma ILD · active not recruiting

Other recruiting trials for Asthma

Currently open trials in the same condition.

NCT07525375 — A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared t · Phase 2 · recruiting
NCT07536256 — Community Connections Through Native Hawaiian Cultural Values to Strengthen Youth Resilience, Health, and Well-Being · NA · recruiting
NCT07556159 — A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice · recruiting
NCT07282886 — VENTURI (VENTilation Using Respiratory Imaging) · Phase 2 · recruiting
NCT07433569 — A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Differ · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04624490 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mario Castro, MD, MPH
Last refreshed: 4 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04624490.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing